ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 462

Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies

Bei-Hung Chang1,2, Lien Quach1, Mary Brophy3, Keri Hannagan4, Edward C. Keystone5, Ted R. Mikuls6 and James R. O'Dell7, 1VA Boston Healthcare System, Boston, MA, 2Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, 3VA Boston Heathcare System, Boston, MA, 4MAVERIC, VA Boston Heathcare System, Boston, MA, 5Medicine, University of Toronto, Toronto, ON, Canada, 6Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adverse events, gastrointestinal complications, Infection, randomized trials and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind, RACAT trial (NEJM 2013;369:307-18), 353 methotrexate suboptimal-responders were randomized to two treatment strategies, either first adding sulfasalazine and hydroxychloroquine, triple therapy (T, N=178), or etanercept (E, N=175) to methotrexate.  Participants without significant improvement in DAS28 at 24 weeks switched treatment while maintaining the blind.  We examined differences between T and E in the most common adverse events reported in the trial, gastrointestinal (GI) toxicity and infections, taking into account possible confounding factors.  

Methods

All adverse events during the trial were recorded and coded by blinded reviewers.  Serious (SAE) or non-serious (NAE) infectious and GI events reported during the intervention period and for 4 weeks after completing the intervention were included in the analysis.  The trial design posed challenges for analysis for 13 switcher patients who had infection (N=8) or GI (N=5) events occur both before and after switching treatment (either T to E or E to T).  For these switchers we included in the analysis only the infections that occurred when patients were currently on T and GI events that occurred when patients were currently on E. This is a conservative approach because infections were the most common side effect for E and GI events were for T.  We calculated the rate of event, total number of events, and the mean duration in the treatment when events occurred.  Logistic and linear regression models were used for treatment comparison with and without controlling for participant characteristics (age, sex, race, BMI, smoking) and comorbidities. 

Results

Participants who were on E were more likely to have infection NAEs (OR= 1.68, p=0.02) and had a higher total number of events (mean of 0.7 vs. 0.4, p=0.004) than participants who were on T. Participants who were on T had a higher number of GI NAEs than those on E (mean 0.55 vs. 0.34, p=0.02). Furthermore, the amount of time on the treatment when the GI events occurred was shorter for T than E (mean duration 10.0 vs. 17.7 weeks, p=0.001). The same conclusions remain after using regression models to control for patient characteristics and comorbidities.  Serious infections and GI events were rare for both treatments. However, there were a greater number of SAE infections that occurred when receiving E than T (12 vs. 4). Pneumonia was the most common SAE infection for both treatments (6 E and 2 T).

Conclusion

In RACAT, infectious NAEs were significantly increased in participants receiving E compared with T even after controlling for participant demographics and comorbidities.  GI NAEs were significantly more frequent in T and occurred earlier in the course of therapy.  Though numbers of SAE were small, there was a trend toward greater number of infectious SAEs when receiving E, which were predominately pneumonias. Our study findings might help clinicians when prescribing medications by considering patients’ tolerance of each treatment’s more common adverse events.


Disclosure:

B. H. Chang,
None;

L. Quach,
None;

M. Brophy,
None;

K. Hannagan,
None;

E. C. Keystone,

Abbott Laboratories,

2,

Amgen Canada,

2,

Astrazeneca Pharmaceuticals LP,

2,

Bristo-Myers Squibb,

2,

F. Hoffman La-Roche Inc.,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Eli Lilly and Company,

2,

Novartis Pharmaceutical Corporation,

2,

Pfizer Inc,

2,

Sanofi-Aventis Pharmaceutical,

2,

Abbott Laboratories,

5,

AstraZeneca,

5,

Biotest,

5,

Bristol-Myers Squibb,

5,

F. Hoffman-La Roche Inc.,

5,

Genentech and Biogen IDEC Inc.,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Eli Lilly and Company,

5,

Merck Pharmaceuticals,

5,

Pfizer Inc,

5,

Abbott Laboratories,

8,

AstraZeneca,

8,

Bristol-Myers Squibb,

8,

F. Hoffman La-Roche Inc.,

8,

Janssen Pharmaceutica Product, L.P.,

8,

Pfizer Inc,

8,

UCB,

8,

Amgen,

8;

T. R. Mikuls,

Genentech/Roche,

2;

J. R. O’Dell,

Abbvie, Lilly, Antares, Medac,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/infections-and-gastrointestinal-side-effects-in-a-comparison-of-rheumatoid-arthritis-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.